Radium-223 dichloride (Ra223) is the first targeted alpha agent approved for treating metastatic castration-resistant prostate cancer (mCRPC) with bone-exclusive disease. A benefit in overall survival and time to the first symptomatic skeletal-related event was shown in the Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. However, this trial did not describe a bone scan response to Ra223, an...
INTRODUÇÃO O adenocarcinoma do pâncreas (PDAC) apresenta-se como um tumor sólido com prognóstico extremamente desfavorável, tendo uma sobrevida global (OS) aos 5 anos de aproximadamente 5%. Na doença metastizada, os esquemas de quimioterapia (QT) aprovados em primeira linha são variados, maioritariamente à base de platino ou gemcitabina. O índice de resposta inflamatória sistémica (SIRI) consiste num scor...
The role of RANKL-RANK pathway in progesterone-driven mammary carcinogenesis and triple negative breast cancer tumorigenesis has been well characterized. However, and despite evidences of the existence of RANK-positive hormone receptor (HR)-positive breast tumors, the implication of RANK expression in HR-positive breast cancers has not been addressed before. Here, we report that RANK pathway affects the express...
Progression through dissemination to tumor-surrounding tissues and metastasis development is a hallmark of cancer that requires continuous cell-to-cell interactions and tissue remodeling. In fact, metastization can be regarded as a tissue disease orchestrated by cancer cells, leading to neoplastic colonization of new organs. Collagen is a major component of the extracellular matrix (ECM), and increasing evidenc...